Prof. Yu Zeng 曾宇
Chief Physician, Professor
Department of Urology, Liaoning Cancer Hospital & Institute, Shenyang
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of benign and malignant urological tumors, including prostate, bladder, kidney, testicular, and adrenal cancers. Performs conventional, minimally invasive, and endoscopic surgeries. Provides comprehensive care for advanced cases and gene-guided personalized therapy.
Dr. Zeng holds a PhD in Surgery from China Medical University and a PhD in Tumor Biology from Kagawa University, Japan. Completed postdoctoral training and served as a lecturer at Johns Hopkins University School of Medicine. Currently Deputy Director of Urology, Professor, and Chief Physician. Published over 50 papers and leads two National Natural Science Foundation projects.
Professional roles
- Senior Member, American Cancer Society
- Senior Member, Society for Basic Urologic Research
- Member, International Society of Urology
- Member, Andrology Branch of Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Zeng Yu). Papers usually list the name as Yu Zeng or Zeng Y.
Selected publications
23 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncogene, 2026 (senior author): Specifically targeted engineered exosomes loaded with circAKR1A1 enhance tumorigenesis and metastasis in prostate cancer by activating the PI3K/Akt signalling pathway. PubMed 42218300
- Ann Med, 2025 (senior author): Mechanisms of neuroendocrine differentiation in castration-resistant prostate cancer and advances in the treatment of neuroendocrine prostate cancer. PubMed 41030221
- Biochim Biophys Acta Rev Cancer, 2025 (senior author): Revolutionizing bladder cancer research: Harnessing 3D organoid technology to decode tumor heterogeneity and propel personalized therapeutics. PubMed 40992706
- Sci Rep, 2025 (senior author): RDM1 plays an oncogenic role in clear cell renal cell carcinoma potentially by modulating MCM2. PubMed 40595023
- Commun Biol, 2025 (senior author): Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses. PubMed 40312519
- Biochim Biophys Acta Rev Cancer, 2024 (senior author): Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis. PubMed 38040267
- Urology, 2023 (senior author): A Laminated Bladder Stone Secondary to an Ectopic Intrauterine Device. PubMed 37598891
- Cancers (Basel), 2023 (senior author): Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment. PubMed 37190171
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion